Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Iterum Therapeutics Focused On First Oral Penem

Executive Summary

Emerging Company Profile: Iterum Therapeutics is developing a Phase III-ready penem antibiotic, sulopenem, which could be the first in its class to be administered orally. It’s the second foray into setting up an anti-infectives-focused company by a team of experienced biotech executives and entrepreneurs that previously took Durata’s dalbavancin through clinical development.

Advertisement

Related Content

Venture Funding Deals: $65m For Iterum's Antibiotic; Genoa's IPF Drug Nets $62m
UK Firms Lead As EU Biotechs Complete Best Ever 1Q VC Fundraising
Actavis builds antibiotic presence with $675m+ Durata deal

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC099108

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel